Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

(2009) M. J. Chapman et al.   EUROPEAN HEART JOURNAL

Laropiprant in Combination With Extended-Release Niacin Does Not Alter Urine 11-Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

(2009) Brett Lauring et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function

(2009) Justin M.S. Lee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mechanism of Action of Niacin

(2008) Vaijinath S. Kamanna et al.   AMERICAN JOURNAL OF CARDIOLOGY

Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins

(2008) Stefania Lamon-Fava et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors

(2008) John F. Paolini et al.   CARDIOLOGY CLINICS

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

(2008) D. Maccubbin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE